Point Therapeutics To Host Webcast On January 31, 2006 Webcast To Present Phase 3 NSCLC Program and Clinical Update
January 20 2006 - 8:15AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced today that it will
host a live webcast on Tuesday, January 31 at 7:30 AM EST. "As the
new year begins, we would like to provide our new investors and
long-term shareholders a clinical update regarding the design and
strategy behind our Phase 3 metastatic non-small cell lung cancer
program and our on-going Phase 2 studies," said Don Kiepert,
Chairman and Chief Executive Officer. The webcast may be accessed
by visiting www.pther.com About Point Therapeutics, Inc.: Point is
developing a family of dipeptidyl peptidase (DPP) inhibitors for
use in cancer, type 2 diabetes and as vaccine adjuvants. The
Company is currently studying its lead product candidate,
talabostat, in a Phase 3 program in metastatic NSCLC. Additionally,
talabostat is being evaluated in several Phase 2 trials; including,
as a single-agent in metastatic melanoma, in combination with
cisplatin in metastatic melanoma, in combination with rituximab in
advanced chronic lymphocytic leukemia, and in combination with
gemcitabine in metastatic pancreatic cancer. Point's portfolio also
includes two other DPP inhibitors in preclinical
development--PT-630 for type 2 diabetes, and PT-510 as a vaccine
adjuvant. Certain statements contained herein are not strictly
historical and are "forward looking" statements as defined in the
Private Securities Litigation Reform Act of 1995. This information
includes statements with respect to the company's clinical
development programs and the timing of initiation and completion of
its clinical trials. Forward-looking statements are statements that
are not historical facts, and can be identified by, among other
things, the use of forward-looking language, such as "believes,"
"feels," "expects," "may," "will," "should," "seeks," "plans,"
"schedule to," "anticipates" or "intends" or the negative of those
terms, or other variations of those terms of comparable language,
or by discussions of strategy or intentions. A number of important
factors could cause actual results to differ materially from those
projected or suggested in the forward looking statement, including
the risk factors described in Point's quarterly report on Form 10-Q
for the quarter ended September 30, 2005 and from time to time in
Point's periodic and other reports filed with the Securities and
Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Oct 2023 to Oct 2024